India to receive stocks of Sputnik V this quarter: Dr Reddy’s

The Hyderabad-based Dr Reddy’s Laboratories (DRL) has begun importing consignments of the Russian-made vaccine against Covid-19, and India can expect to receive stocks of Sputnik V at some point between later this month and June.

However, the availability of the vaccine in India will, largely depend on factors such as the number of doses that the government wishes to procure, the price, and the capacity of the country’s cold chain system to distribute the vaccine.

As part of DRL’s contract with the Russian Direct Investment Fund (RDIF), it is expected to receive around 250 million doses of Spuntik V, Deepak Sapra, the company’s CEO, API and Services, said on Wednesday.

Sputnik V being a double-dose vaccine, this would be sufficient for 125 million people, but DRL can procure more doses from RDIF for India with “mutual consent”.

While discussions continue with the government over the use of Sputnik V in India’s immunization campaign, the company will start imports “this quarter”, Sapra said.

As far as the price of the vaccine is concerned, DRL said it could not comment or speculate on the price of the vaccine at this stage. Clarity on price and the number of doses that India will use will emerge “in the next few weeks”, company executives said.

The Logistics of Sputnik V

The company informed that it is yet to determine the quantities (and) the place where the vaccine will go.

 The priorities of the government and the discussions we will have with them and the other stakeholders will determine where all Sputnik is distributed,” he said. “The objective is that, over a period of time, we will have enough vaccines to be made available throughout the country.”

As of now, DRL has received restricted emergency use permission to supply the vaccine in liquid form. Additional stability data to receive approval to use a ‘freeze-dried’ form will be made available “in a few months”, which may ease cold storage requirements by allowing the vaccine to be stored at between 2°C and 8°C.

Until then the company has made necessary logistics arrangement to develop and store the vaccine at much lower temperatures of minus 18°C to minus 22°C, at which its safety and potency can be ensured.

“What we have done at Dr Reddy’s is to line up the cold chain, and we have made the logistics arrangements to ensure delivery up to the last mile throughout the country. We have tested it out in a few simulation scenarios from Hyderabad, as far east as the Northeast – Manipur, as far north as Ladakh, and as far south as Tamil Nadu,” Sapra said.

“We have also lined up a solution that involves certain compact boxes which can be transported in a very easy manner throughout the country. Through a combination of air transport and road transportation, we believe we will be able to take this vaccine to all parts of the country at the required temperature condition,” he said.

Further adding he informed that the company will also be leveraging some of the infrastructure of the existing (government) immunisation programme that is in place to ensure that this is transported and stored in a safe manner,

The vaccine is expected to be available in larger quantities in the July-September quarter, once the Indian companies that have tied up with RDIF begin manufacturing in the country, Sapra said. RDIF has agreements with Gland Pharma, Stelis Biopharma, Hetero Biopharma, Panacea Biotec, Virchow Biotech, and Shilpa Medicare to manufacture 850 million doses of Sputnik V.

Once manufacturing begins in India one can expect the availability of the vaccine in large quantities with India producing 60-70% of the global volumes of Sputnik V, however, until then the vaccine will be imported from Russia.

DRL informs that the vaccine produced in the country will mostly be utilized within the nation.

Source: Indian Express

Leave a Reply

Your email address will not be published. Required fields are marked *